Enhanced Composition for Promoting FGF21 Secretion

An improved composition for promoting the secretion of fibroblast growth factor 21 (FGF21) by incorporating a prebiotic that selectively stimulates the growth of a specific Bifidobacterium bacterium, leading to enhanced efficacy and safety.

The original patent disclosed a composition for promoting FGF21 secretion using a Bifidobacterium bacterium. However, the patent did not address the limitation of potential interference from other gut microbiota, which could affect the efficacy of the composition. The new inventive concept addresses this limitation by incorporating a prebiotic that selectively stimulates the growth of the specific Bifidobacterium bacterium, ensuring optimal FGF21 secretion.

The enhanced composition comprises a Bifidobacterium bacterium, specifically Bifidobacterium breve M-16V (NITE BP-02622), and a prebiotic, such as inulin, at a concentration of 0.5% to 5%. The prebiotic selectively stimulates the growth of the Bifidobacterium bacterium, promoting its colonization and activity in the gut. This results in enhanced FGF21 secretion, which can be beneficial for various health conditions. The composition can be administered orally, and the dosage can be adjusted based on individual needs. A kit for promoting FGF21 secretion can also be provided, comprising the composition and instructions for use.

The new claims introduce the concept of using a prebiotic to selectively stimulate the growth of the Bifidobacterium bacterium, which is not disclosed in the original patent. This innovation provides a significant improvement over the prior art, as it enhances the efficacy and safety of the composition.

Alternative prebiotics, such as fructooligosaccharides or galactooligosaccharides, can be used in place of inulin. The composition can also be formulated in various forms, such as capsules, tablets, or powders, to suit different administration routes and patient preferences.

The enhanced composition has potential commercial applications in the fields of nutrition, pharmaceuticals, and healthcare. The target market includes individuals seeking to improve their metabolic health, as well as those with specific health conditions, such as diabetes or obesity, where FGF21 secretion is beneficial.